Swedish Orphan Biovitrum AB (publ) - Special Call

Group 1 - The company Sobi has received acceptance from the FDA for the filing package related to the NASP program for uncontrolled gout [1] - Dr. Herbert Baraf, a prominent figure in rheumatology, is involved in the discussion, highlighting the clinical expertise supporting the NASP program [2][3] - The NASP program, formerly known as SEL-212, has been under development for over 7 years, indicating a long-term commitment to addressing gout treatment [4]